Vertex Pharma (VRTX) Reports Statistically Significant Data from VX-809 and KALYDECO Phase 2 in Lung Function
Go back to Vertex Pharma (VRTX) Reports Statistically Significant Data from VX-809 and KALYDECO Phase 2 in Lung Function| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 540.26 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $540.26 | 52 Week High | $134.71 | |||
| Open | $540.26 | 52 Week Low | $73.31 | |||
| Day High | $540.26 | P/E | N/A | |||
| Day Low | $540.26 | EPS | $-1.98 | |||
| Volume | 98 | |||||
